Test Price
2,800 AEDโ Home Collection Available
MARS2 Gene Spastic Ataxia Type 3 (Autosomal Recessive) Genetic Test in UAE | 2800 AED
DHA-Approved ClinicExecutive Summary & Core Metrics
- Diagnostic Precision: 99.9% analytical sensitivity via ISO 9001:2015 accredited NGS platform.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Support: Complimentary post-test teleconsultation for interpretation with a DHA-licensed genetics specialist.
- Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The MARS2 gene test employs next-generation sequencing to detect pathogenic variants responsible for autosomal recessive spastic ataxia type 3, a progressive neurodegenerative disorder marked by spasticity and cerebellar dysfunction.
| Feature | Our MARS2 NGS Test | Closest Alternative (Whole Exome Sequencing) |
|---|---|---|
| Methodology | Targeted NGS with deep (>100ร) coverage of the entire MARS2 gene, including intronโexon boundaries | Whole exome capture; may miss deep intronic or regulatory variants; requires reflex to Sanger confirmation |
| Diagnostic Sensitivity | >99.9% for known pathogenic variants in MARS2 | ~98% depending on capture kit; often lower coverage for specific ataxia genes |
| Turnaround Time | 3โ4 weeks | 5โ7 weeks (plus bioinformatics analysis) |
| Price | 2,800 AED | approx. 3,500โ4,500 AED |
| Pre-test Counseling | Included genetic counseling session with pedigree chart | Often not included; may require separate appointment |
Physician Insight & Safety Protocols
"As a Consultant Medical Genetics, I confirm that this targeted NGS test provides definitive molecular diagnosis for autosomal recessive spastic ataxia type 3. However, results must always be interpreted within the full clinical context, including neurological examination and family pedigree. A negative result does not rule out the condition and may warrant further investigation for phenocopies. Genetic counseling is integral to this process."
โ Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403
Medication Advisory
Do not alter or discontinue any prescribed medication based on genetic test results without consulting your treating physician. This test is intended for diagnostic confirmation and does not replace ongoing symptomatic management.
Safety Exclusion Criteria & Red Flags
- Exclusion Criteria: Recent allogeneic blood transfusion (<4 weeks), known severe coagulopathy requiring specialist collection, or inability to provide informed consent.
- Emergency Red Flags: Seek immediate medical attention if you experience sudden loss of balance, acute vision loss, first-time seizures, or rapid worsening of spasticity with respiratory difficulty.
- All home collections are performed by DHA-licensed phlebotomists under strict aseptic protocols.
Patient FAQ & Clinical Guidance
1. What is the MARS2 gene and what does this test detect?
Next-generation sequencing of the MARS2 gene detects mutations causing autosomal recessive spastic ataxia type 3. This comprehensive analysis reads the entire coding region to identify point mutations, small insertions/deletions, and copy number variants associated with the phenotype.
2. Who should consider this test?
Those with progressive gait disturbance, spasticity, and a family history of ataxia should consider MARS2 gene testing. It is clinically indicated for individuals presenting with early-onset spastic paraparesis, dysarthria, and cerebellar atrophy on MRI, especially in consanguineous families.
3. What sample is required and how is collection performed?
A simple blood draw or FTA card is collected by licensed phlebotomists at your home. Options include whole blood (EDTA tube), extracted DNA, or a single drop on an FTA card. All samples are transported in temperature-controlled containers.
UAE Regulatory & Data Privacy Adherence
- DHA Facility License: 1143 โ Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE
- ISO 9001:2015 Certification: Certificate No. INT/EGQ/2509DA/3139
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL): Genetic data is encrypted endโtoโend and never shared without explicit consent.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields: All health data processing complies with secure ICT standards.
- Federal Decree-Law No. 4 of 2016 on Medical Liability: Patient safety and consent procedures adhere to this law.
- Pre-test genetic counseling and pedigree charting are integral to the service, aligning with DHA clinical governance.
Clinical & Logistical Metadata
| Test Name | MARS2 Gene Spastic Ataxia Type 3 (Autosomal Recessive) Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3โ4 weeks |
| Sample Type / Matrix | Whole blood (EDTA) or FTA card |
| Methodology Used | Targeted Next-Generation Sequencing (NGS) with deep coverage |
| ICD-10-CM Code | G11.8 (Other hereditary ataxias) |
| LOINC Code | 48726-0 (Genetic analysis, DNA sequence analysis) |
| DHA Facility License & Laboratory Address | License 1143 โ Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians